NCT02708186View on ClinicalTrials.gov

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Dementia With Lewy BodiesREM Sleep Behavior DisorderParkinson's Disease Dementia
Interventions
DRUG

Nelotanserin

once daily, oral, 20-mg tablets

DRUG

Placebo

once daily, oral, matching tablets

Trial Locations (23)

27514

US101, Chapel Hill

28562

US159, New Bern

30331

US163, Atlanta

32174

US152, Ormond Beach

32751

US180, Maitland

32806

US113, Orlando

33613

US153, Tampa

34471

US154, Ocala

35294

US120, Birmingham

38613

US128, Memphis

43210

US105, Columbus

44195

US104, Cleveland

45229

US111, Cincinnati

46202

US107, Indianapolis

58103

US147, Fargo

66214

US132, Lenexa

68526

US129, Lincoln

72205

US143, Little Rock

78229

US131, San Antonio

80113

US122, Englewood

85013

US164, Phoenix

85351

US145, Sun City

02865

US173, Lincoln

Sponsors
All Listed Sponsors
lead

Axovant Sciences Ltd.

INDUSTRY